What is Pentoxifylline?
Pentoxifylline is a methylxanthine derivative medication approved by the FDA for treating intermittent claudication caused by peripheral arterial disease, though its clinical effectiveness is marginal and it serves only as a second-line alternative to cilostazol. 1
Drug Classification and Mechanism
Pentoxifylline is a hemorheological agent—meaning it affects blood flow properties rather than acting as a simple vasodilator. 2 The drug works through multiple mechanisms:
- Improves red blood cell deformability (flexibility), allowing better passage through small vessels
- Decreases blood and plasma viscosity (thickness)
- Inhibits neutrophil adhesion and activation
- Reduces platelet aggregation potential
- May lower plasma fibrinogen concentrations (though results are inconsistent across studies) 2, 3, 4
The medication also has immunomodulatory effects, including decreased production of tumor necrosis factor-alpha and reduced inflammatory responses. 4, 5
FDA-Approved Indication
The only FDA-approved use is for intermittent claudication due to chronic occlusive arterial disease of the limbs. 1 The standard dosing is 400 mg orally three times daily. 2, 6
Important Caveat
Pentoxifylline is not intended to replace definitive therapy such as surgical bypass or removal of arterial obstructions—it only improves function and symptoms. 1
Clinical Effectiveness: The Evidence is Weak
The ACC/AHA guidelines give pentoxifylline only a Class IIb recommendation (may be considered) with the explicit statement that "clinical effectiveness is marginal and not well established." 2, 6
Walking Distance Improvements
Meta-analyses show pentoxifylline produces only modest improvements:
- Pain-free walking distance increases by 21-29 meters
- Maximal walking distance increases by 43-48 meters 2
In a head-to-head trial of 471 patients comparing pentoxifylline, cilostazol, and placebo: there was no significant difference between pentoxifylline and placebo, while cilostazol clearly improved both pain-free and maximal walking distance. 2 This is why pentoxifylline is relegated to second-line status.
Does Not Improve Hemodynamics
Pentoxifylline does not increase the ankle-brachial index (ABI) at rest or after exercise, indicating it doesn't meaningfully improve blood flow measurements. 2
Safety Profile
Pentoxifylline is generally well-tolerated with no life-threatening side effects reported in trials to date. 2 Common adverse effects include:
- Sore throat
- Dyspepsia (indigestion)
- Nausea
- Diarrhea 2
Important Drug Interactions
- Warfarin: Increased prothrombin time and bleeding risk—requires more frequent INR monitoring 1
- Theophylline: Increased theophylline levels and potential toxicity—monitor levels 1
- NSAIDs and antiplatelet agents: Increased bleeding risk 1
- Strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): Increased pentoxifylline exposure 1
Uses NOT Recommended
Critical Limb Ischemia
Parenteral pentoxifylline is NOT useful for critical limb ischemia (Class III recommendation). 2 Two trials of intravenous pentoxifylline 600 mg twice daily showed conflicting results, with one showing reduced pain and the other showing no benefit. 2
Alcoholic Hepatitis
Pentoxifylline is no longer recommended for severe alcoholic hepatitis. 7 While an initial trial suggested mortality benefit, subsequent high-quality trials (including the STOPAH trial) and meta-analyses of individual patient data failed to demonstrate any survival benefit. 7
Other Investigated Uses
Pentoxifylline has been studied for various conditions due to its anti-inflammatory and hemorheological properties, including:
- Venous leg ulcers (some evidence of benefit) 8, 9
- Cerebrovascular disease 3
- Sickle cell disease 3
- Major depressive disorder (emerging evidence) 10
However, none of these uses are FDA-approved, and the evidence quality varies considerably.
Bottom Line for Clinical Practice
Pentoxifylline is a hemorheological agent with marginal benefit for intermittent claudication. If you're treating claudication, start with cilostazol (unless the patient has heart failure)—it has proven superiority. 6 Only consider pentoxifylline as a second-line option when cilostazol fails, is contraindicated, or not tolerated. The expected clinical improvement will be modest at best, and you should set realistic expectations with patients about the limited benefit they may experience.